A cross-sectional analysis assessing non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies
Latest Information Update: 01 Jun 2022
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
Most Recent Events
- 01 Jun 2022 New trial record
- 16 May 2022 Results published in the Respiratory Medicine